1.25
0.46 (58.23%)
| Previous Close | 0.790 |
| Open | 0.808 |
| Volume | 3,767,197 |
| Avg. Volume (3M) | 1,391,730 |
| Market Cap | 4,254,429 |
| Price / Sales | 11.80 |
| Price / Book | 2.72 |
| 52 Weeks Range | |
| Earnings Date | 1 Apr 2025 |
| Operating Margin (TTM) | -22,618.75% |
| Diluted EPS (TTM) | -24.00 |
| Quarterly Revenue Growth (YOY) | -60.00% |
| Total Debt/Equity (MRQ) | 116.79% |
| Current Ratio (MRQ) | 0.260 |
| Operating Cash Flow (TTM) | -12.43 M |
| Levered Free Cash Flow (TTM) | -11.19 M |
| Return on Assets (TTM) | -98.37% |
| Return on Equity (TTM) | -3,138.91% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | AIM ImmunoTech Inc. | - | - |
AIStockmoo Score
| Analyst Consensus | 2.0 |
| Insider Activity | 1.5 |
| Price Volatility | -2.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -0.5 |
| Average | 0.20 |
|
AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's lead product candidate is Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS). It is also developing Ampligen for the treatment of renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, prostate and pancreatic cancer, myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. In addition, the company provides Alferon N Injection, an injectable formulation of natural alpha interferon to treat human papilloma viruses, and genital warts, a sexually transmitted disease. AIM ImmunoTech Inc. has agreements with Amarex Clinical Research LLC; Pharmaceutics International Inc.; Polysciences Inc.; and University of Cagliari Dipartimento di Scienze della Vita e dell'Ambiente. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was incorporated in 1966 and is headquartered in Ocala, Florida. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| % Held by Insiders | 12.10% |
| % Held by Institutions | 10.63% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Sabby Management, Llc | 30 Sep 2025 | 28,884 |
| Community Bank, N.A. | 31 Dec 2025 | 132 |
| Hoey Investments, Inc | 31 Dec 2025 | 10 |
| Steward Partners Investment Advisory, Llc | 31 Dec 2025 | 2 |
| Intesa Sanpaolo Wealth Management | 31 Dec 2025 | 1 |
| Farther Finance Advisors, Llc | 31 Dec 2025 | 1 |
| Harbour Investments, Inc. | 31 Dec 2025 | 0 |
No data within this time range.
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| CHEMEROW DAVID I. | 1.19 | - | 2,800 | 3,340 |
| Aggregate Net Quantity | 2,800 | |||
| Aggregate Net Value ($) | 3,340 | |||
| Aggregate Avg. Buy ($) | 1.19 | |||
| Aggregate Avg. Sell ($) | - | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| CHEMEROW DAVID I. | Director | 05 Feb 2026 | Acquired (+) | 2,800 | 1.19 | 3,340 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |